Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR L858R/T790M /ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers
Journal of Medicinal Chemistry · 22.02.2024 · 67 (4) · 2777-2801
DOI: 10.1021/acs.jmedchem.3c01934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.02.2024. Verfasst von Aoxue Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sich…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Acrylamides, Aniline Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Sichuan University, West China Hospital, Sichuan University, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Activation of the alternative pathways and abnormal signaling transduction are frequently observed in third-generation EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors)-resistant patients. Wherein, hyperphosphorylation of ACK1 contributes to EGFR-TKIs acquired resistance. Dual inhibition of EGFRL858R/T790M and ACK1 might improve therapeutic efficacy and overcome resistance in lung cancers treatment. Here, we identified a EGFRL858R/T790M/ACK1 dual-targeting compound 21a with aminoquinazoline scaffold, which showed excellent inhibitory activities against EGFRL858R/T790M (IC50 = 23 nM) and ACK1 (IC50 = 263 nM). The cocrystal and docking analysis showed that 21a occupied the ATP binding pockets of EGFRL858R/T790M and ACK1. Moreover, 21a showed potent antiproliferative activities against the H1975 cells, MCF-7 cells and osimertinib-resistant cells AZDR. Further, 21a showed significant antitumor effects and good safety in ADZR xenograft-bearing mice. Taken together, 21a was a potent dual inhibitor of EGFRL858R/T790M/ACK1, which is deserved as a potential lead for overcoming acquired resistance to osimertinib during the EGFR-targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, National Clinical Research Center for Geriatrics, West C…
ORCID-Profile: Yuxi Wang, Guan Wang, Liang Ouyang
Förderung
- Sichuan University
- West China Hospital, Sichuan University
- Natural Science Foundation of Sichuan Province
- National Natural Science Foundation of China
- Postdoctoral Fellowship Program of CPSF
Zitieren
APA
Wang, A., Shuai, W., Wu, C., Pei, J., Yang, P., Wang, X., Li, S., Liu, J., Wang, Y., Wang, G., & Ouyang, L. (2024). Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR L858R/T790M /ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers. Journal of Medicinal Chemistry, 67(4), 2777-2801. https://doi.org/10.1021/acs.jmedchem.3c01934
Vancouver
Wang A, Shuai W, Wu C, Pei J, Yang P, Wang X, et al. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR L858R/T790M /ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers. Journal of Medicinal Chemistry. 2024;67(4):2777-2801. doi:10.1021/acs.jmedchem.3c01934
BibTeX
@article{Wang2024,
author = {Wang, Aoxue and Shuai, Wen and Wu, Chengyong and Pei, Junping and Yang, Panpan and Wang, Xin and Li, Shutong and Liu, Jiaxi and Wang, Yuxi and Wang, Guan and Ouyang, Liang},
title = {Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR L858R/T790M /ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {4},
pages = {2777--2801},
doi = {10.1021/acs.jmedchem.3c01934}
}
EUVIMED